Bio-Gene Technology Valuation
| BGT Stock | 0.03 0 10.00% |
Bio-Gene Technology seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Bio Gene Technology from analyzing the firm fundamentals such as Return On Equity of -0.94, current valuation of 5.46 M, and Shares Owned By Insiders of 43.33 % as well as examining its technical indicators and probability of bankruptcy.
Price Book 5.0099 | Enterprise Value 5.5 M | Enterprise Value Ebitda (2.71) | Price Sales 362.7154 | Enterprise Value Revenue 10.7329 |
Overvalued
Today
Please note that Bio-Gene Technology's price fluctuation is out of control at this time. Calculation of the real value of Bio Gene Technology is based on 3 months time horizon. Increasing Bio-Gene Technology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Bio-Gene Technology's intrinsic value may or may not be the same as its current market price of 0.03, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.033 | Real 0.0302 | Hype 0.03 | Naive 0.0375 |
The intrinsic value of Bio-Gene Technology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bio-Gene Technology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bio Gene Technology helps investors to forecast how Bio-Gene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio-Gene Technology more accurately as focusing exclusively on Bio-Gene Technology's fundamentals will not take into account other important factors: Bio-Gene Technology Cash |
|
Bio-Gene Technology Total Value Analysis
Bio Gene Technology is currently anticipated to have takeover price of 5.46 M with market capitalization of 6.64 M, debt of 368.45 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bio-Gene Technology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.46 M | 6.64 M | 368.45 K |
Bio-Gene Technology Investor Information
About 43.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.01. Bio Gene Technology had not issued any dividends in recent years. Based on the key measurements obtained from Bio-Gene Technology's financial statements, Bio Gene Technology is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Bio-Gene Technology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bio-Gene Technology has an asset utilization ratio of 0.58 percent. This implies that the Company is making USD0.005798 for each dollar of assets. An increasing asset utilization means that Bio Gene Technology is more efficient with each dollar of assets it utilizes for everyday operations.Bio-Gene Technology Ownership Allocation
Bio-Gene Technology holds a total of 201.36 Million outstanding shares. Bio Gene Technology retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bio-Gene Technology Profitability Analysis
The company reported the revenue of 18.32 K. Net Loss for the year was (2.41 M) with loss before overhead, payroll, taxes, and interest of (558.91 K).About Bio-Gene Technology Valuation
The stock valuation mechanism determines Bio-Gene Technology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Bio Gene Technology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bio-Gene Technology. We calculate exposure to Bio-Gene Technology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bio-Gene Technology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -346.7 K | -329.3 K |
Additional Tools for Bio-Gene Stock Analysis
When running Bio-Gene Technology's price analysis, check to measure Bio-Gene Technology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio-Gene Technology is operating at the current time. Most of Bio-Gene Technology's value examination focuses on studying past and present price action to predict the probability of Bio-Gene Technology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio-Gene Technology's price. Additionally, you may evaluate how the addition of Bio-Gene Technology to your portfolios can decrease your overall portfolio volatility.